Revisiting the role of novel weight management medications and bariatric surgery
The global prevalence of obesity has continued to rise globally over the past two decades. Obesity is closely associated with increased risk of metabolic， cardiovascular， and other diseases， reduced quality of life and shortened life expectancy. Bariatric surgery is recognized as a highly effective...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of New Medicine
2025-06-01
|
| Series: | Xin yixue |
| Subjects: | |
| Online Access: | https://www.xinyixue.cn/fileup/0253-9802/PDF/1751417413139-713343897.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849428995290955776 |
|---|---|
| author | LIANG Hui |
| author_facet | LIANG Hui |
| author_sort | LIANG Hui |
| collection | DOAJ |
| description | The global prevalence of obesity has continued to rise globally over the past two decades. Obesity is closely associated with increased risk of metabolic， cardiovascular， and other diseases， reduced quality of life and shortened life expectancy. Bariatric surgery is recognized as a highly effective weight loss measure， with studies showing its effects lasting more than 10 years. Moreover， bariatric surgery not only leads to weight loss but also improves cardiovascular and metabolic risk factors， such as type 2 diabetes， hypertension， and dyslipidaemia. It also demonstrates sound therapeutic effects on other obesity-related diseases， such as polycystic ovary syndrome（PCOS）， sleep apnea， and osteoarthritis. Studies have shown that patients undergoing bariatric surgery have reduced all-cause mortality， cardiovascular events and cancer risk.The emergence of glucagon-like peptide-1 receptor agonist therapies （GLP-1 RA， semaglutide） and GLP-1/GIP dual receptor agonist （tirzepatide） has demonstrated significant weight loss effects with continuous use. Similar to bariatric surgery， these drugs can improve outcomes for type 2 diabetes， cardiovascular mortality， and other obesity-related complications. The article compares bariatric surgery with enteral proinsulin agonists in terms of weight loss efficacy， complication rates， risk profile， cost-effectiveness， and accessibility， explores the value and promise of these popular drugs and bariatric surgery in the treatment of obesity. |
| format | Article |
| id | doaj-art-84bc8c397fc9412c8e1e0efb6febfef1 |
| institution | Kabale University |
| issn | 0253-9802 |
| language | zho |
| publishDate | 2025-06-01 |
| publisher | Editorial Office of Journal of New Medicine |
| record_format | Article |
| series | Xin yixue |
| spelling | doaj-art-84bc8c397fc9412c8e1e0efb6febfef12025-08-20T03:28:29ZzhoEditorial Office of Journal of New MedicineXin yixue0253-98022025-06-0156655355910.12464/j.issn.0253-9802.2025-0156Revisiting the role of novel weight management medications and bariatric surgeryLIANG Hui0Department of General Surgery， Division of Bariatric & Metabolic Surgery， Jiangsu Province Hospital / the First Affiliated Hospital of Nanjing Medical University， Nanjing 210029， ChinaThe global prevalence of obesity has continued to rise globally over the past two decades. Obesity is closely associated with increased risk of metabolic， cardiovascular， and other diseases， reduced quality of life and shortened life expectancy. Bariatric surgery is recognized as a highly effective weight loss measure， with studies showing its effects lasting more than 10 years. Moreover， bariatric surgery not only leads to weight loss but also improves cardiovascular and metabolic risk factors， such as type 2 diabetes， hypertension， and dyslipidaemia. It also demonstrates sound therapeutic effects on other obesity-related diseases， such as polycystic ovary syndrome（PCOS）， sleep apnea， and osteoarthritis. Studies have shown that patients undergoing bariatric surgery have reduced all-cause mortality， cardiovascular events and cancer risk.The emergence of glucagon-like peptide-1 receptor agonist therapies （GLP-1 RA， semaglutide） and GLP-1/GIP dual receptor agonist （tirzepatide） has demonstrated significant weight loss effects with continuous use. Similar to bariatric surgery， these drugs can improve outcomes for type 2 diabetes， cardiovascular mortality， and other obesity-related complications. The article compares bariatric surgery with enteral proinsulin agonists in terms of weight loss efficacy， complication rates， risk profile， cost-effectiveness， and accessibility， explores the value and promise of these popular drugs and bariatric surgery in the treatment of obesity.https://www.xinyixue.cn/fileup/0253-9802/PDF/1751417413139-713343897.pdfbariatric surgery|glp-1 receptor agonists|incretin|semaglutide|tirzepatide|obesity |
| spellingShingle | LIANG Hui Revisiting the role of novel weight management medications and bariatric surgery Xin yixue bariatric surgery|glp-1 receptor agonists|incretin|semaglutide|tirzepatide|obesity |
| title | Revisiting the role of novel weight management medications and bariatric surgery |
| title_full | Revisiting the role of novel weight management medications and bariatric surgery |
| title_fullStr | Revisiting the role of novel weight management medications and bariatric surgery |
| title_full_unstemmed | Revisiting the role of novel weight management medications and bariatric surgery |
| title_short | Revisiting the role of novel weight management medications and bariatric surgery |
| title_sort | revisiting the role of novel weight management medications and bariatric surgery |
| topic | bariatric surgery|glp-1 receptor agonists|incretin|semaglutide|tirzepatide|obesity |
| url | https://www.xinyixue.cn/fileup/0253-9802/PDF/1751417413139-713343897.pdf |
| work_keys_str_mv | AT lianghui revisitingtheroleofnovelweightmanagementmedicationsandbariatricsurgery |